
Incyte Corporation: shareholders and insiders
Price
$114.62
November 20, 2026Market cap $22.8B
What Ploutos Investor adds for Incyte
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 20, 2025 to Nov 18, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$68M
8 people
From Nov 20, 2025 to Nov 20, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan100%
- The rest0%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 20, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $59M by 7 people
- 2025: no buys, sold $9.0M by 4 people
- 2026: no buys, sold $59M by 7 people
- Nov 16, 2026Steven H SteinCMO & Head of Late-Stage Dev.Kind10b5-1
- Nov 16, 2026Steven H SteinCMO & Head of Late-Stage Dev.Kind10b5-1
- Nov 16, 2026Pablo J CagnoniPresident, Global Head of R&DKind10b5-1
- Nov 16, 2026Pablo J CagnoniPresident, Global Head of R&DKind10b5-1
- Nov 16, 2026Pablo J CagnoniPresident, Global Head of R&DKind10b5-1
- Nov 16, 2026Pablo J CagnoniPresident, Global Head of R&DKind10b5-1
- Nov 16, 2026Pablo J CagnoniPresident, Global Head of R&DKind10b5-1
- Nov 16, 2026Pablo J CagnoniPresident, Global Head of R&DKind10b5-1
- Nov 13, 2026Lee HeesonEVP, Head of Incyte IntlKind10b5-1
- Nov 13, 2026Lee HeesonEVP, Head of Incyte IntlKind10b5-1
- Nov 13, 2026Lee HeesonEVP, Head of Incyte IntlKind10b5-1
- Nov 13, 2026Lee HeesonEVP, Head of Incyte IntlKind10b5-1
- Nov 13, 2026Lee HeesonEVP, Head of Incyte IntlKind10b5-1
- Nov 6, 2026Steven H SteinCMO & Head of Late-Stage Dev.Kind10b5-1
- Nov 6, 2026Steven H SteinCMO & Head of Late-Stage Dev.Kind10b5-1
- Nov 6, 2026Steven H SteinCMO & Head of Late-Stage Dev.Kind10b5-1
- Nov 6, 2026Steven H SteinCMO & Head of Late-Stage Dev.Kind10b5-1
- Nov 6, 2026Steven H SteinCMO & Head of Late-Stage Dev.Kind10b5-1
- Nov 6, 2026Steven H SteinCMO & Head of Late-Stage Dev.Kind10b5-1
- Nov 6, 2026Steven H SteinCMO & Head of Late-Stage Dev.Kind10b5-1
- Nov 6, 2026Steven H SteinCMO & Head of Late-Stage Dev.Kind10b5-1
- Nov 6, 2026Steven H SteinCMO & Head of Late-Stage Dev.Kind10b5-1
- Nov 6, 2026Steven H SteinCMO & Head of Late-Stage Dev.Kind10b5-1
- Nov 6, 2026Steven H SteinCMO & Head of Late-Stage Dev.Kind10b5-1
- Nov 6, 2026Steven H SteinCMO & Head of Late-Stage Dev.Kind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | Steven H SteinCMO & Head of Late-Stage Dev. | 10b5-1 | 576 | $68.25 | $39.3K | Form 4 |
| Nov 16, 2026 | Steven H SteinCMO & Head of Late-Stage Dev. | 10b5-1 | 576 | $121.98 | $70.3K | Form 4 |
| Nov 16, 2026 | Pablo J CagnoniPresident, Global Head of R&D | 10b5-1 | 455 | $61.18 | $27.8K | Form 4 |
| Nov 16, 2026 | Pablo J CagnoniPresident, Global Head of R&D | 10b5-1 | 422 | $61.76 | $26.1K | Form 4 |
| Nov 16, 2026 | Pablo J CagnoniPresident, Global Head of R&D | 10b5-1 | 926 | $64.25 | $59.5K | Form 4 |
| Nov 16, 2026 | Pablo J CagnoniPresident, Global Head of R&D | 10b5-1 | 839 | $71.93 | $60.3K | Form 4 |
| Nov 16, 2026 | Pablo J CagnoniPresident, Global Head of R&D | 10b5-1 | 877 | $121.98 | $107.0K | Form 4 |
| Nov 16, 2026 | Pablo J CagnoniPresident, Global Head of R&D | 10b5-1 | 1,765 | $120.46 | $212.6K | Form 4 |
| Nov 13, 2026 | Lee HeesonEVP, Head of Incyte Intl | 10b5-1 | 1,471 | $121.89 | $179.3K | Form 4 |
| Nov 13, 2026 | Lee HeesonEVP, Head of Incyte Intl | 10b5-1 | 2,200 | $120.44 | $265.0K | Form 4 |
| Nov 13, 2026 | Lee HeesonEVP, Head of Incyte Intl | 10b5-1 | 874 | $121.16 | $105.9K | Form 4 |
| Nov 13, 2026 | Lee HeesonEVP, Head of Incyte Intl | 10b5-1 | 3,700 | $120.33 | $445.2K | Form 4 |
| Nov 13, 2026 | Lee HeesonEVP, Head of Incyte Intl | 10b5-1 | 2,449 | $121.13 | $296.7K | Form 4 |
| Nov 6, 2026 | Steven H SteinCMO & Head of Late-Stage Dev. | 10b5-1 | 8,539 | $68.62 | $585.9K | Form 4 |
| Nov 6, 2026 | Steven H SteinCMO & Head of Late-Stage Dev. | 10b5-1 | 12.3K | $72.27 | $891.5K | Form 4 |
| Nov 6, 2026 | Steven H SteinCMO & Head of Late-Stage Dev. | 10b5-1 | 16.4K | $80.50 | $1.3M | Form 4 |
| Nov 6, 2026 | Steven H SteinCMO & Head of Late-Stage Dev. | 10b5-1 | 15.1K | $74.78 | $1.1M | Form 4 |
| Nov 6, 2026 | Steven H SteinCMO & Head of Late-Stage Dev. | 10b5-1 | 23.5K | $77.67 | $1.8M | Form 4 |
| Nov 6, 2026 | Steven H SteinCMO & Head of Late-Stage Dev. | 10b5-1 | 18.3K | $61.76 | $1.1M | Form 4 |
| Nov 6, 2026 | Steven H SteinCMO & Head of Late-Stage Dev. | 10b5-1 | 19.7K | $61.18 | $1.2M | Form 4 |
| Nov 6, 2026 | Steven H SteinCMO & Head of Late-Stage Dev. | 10b5-1 | 12.3K | $64.25 | $790.6K | Form 4 |
| Nov 6, 2026 | Steven H SteinCMO & Head of Late-Stage Dev. | 10b5-1 | 6,907 | $68.25 | $471.4K | Form 4 |
| Nov 6, 2026 | Steven H SteinCMO & Head of Late-Stage Dev. | 10b5-1 | 16.4K | $85.01 | $1.4M | Form 4 |
| Nov 6, 2026 | Steven H SteinCMO & Head of Late-Stage Dev. | 10b5-1 | 12.7K | $90.56 | $1.2M | Form 4 |
| Nov 6, 2026 | Steven H SteinCMO & Head of Late-Stage Dev. | 10b5-1 | 15.1K | $83.58 | $1.3M | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 28, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by INCY's officers and directors from 2006 up to November 19, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Baker Bros. Advisors LPwith 6 more personsShare of class15.6%
- BlackRock, Inc.Share of class7.80%
- Vanguard Capital ManagementShare of class6.32%
- Dodge & CoxShare of class5.00%
- State StreetShare of class5.00%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Baker Bros. Advisors LPwith 6 more persons | 15.6% | 31.23M | May 11, 20262 filings since Feb 10, 2026 | 13D/A | |
| BlackRock, Inc. | 7.80% | 15.24M | Oct 17, 2025 | 13G/A | |
| Vanguard Capital Management | 6.32% | 12.59M | Apr 30, 2026 | 13G | |
| Dodge & Cox | 5.00% | 10.06M | Nov 12, 20262 filings since May 14, 2026 | 13G/A | |
| State Street | 5.00% | 9.68M | Nov 10, 2025 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Baker Bros. Advisors LP15.6%From the filing of May 11, 2026
Item 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows: On May 8, 2026 the Adviser acquired beneficial ownership of 15,000 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer"), as a result of the exercise of 15,000 options to purchase Common Stock at $84.53 per share (the "Exercised Stock Options") held directly by Julian C. Baker. Julian C. Baker currently serves on the Issuer's board of directors (the "Board") as a representative of the Funds. The policy of the Funds and the Adviser does not permit managing members of the Adviser GP or full-time employees of the Adviser to receive compensation for serving as directors of the Issuer,…
From the filing of May 11, 2026
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- The Vanguard Group0.00%Mar 27, 202613G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Renaissance TechnologiesIn the quarter-5.3%
- AQR CapitalIn the quarter+4.9%
- Bridgewater (Dalio)In the quarter+21%
- Glenview CapitalIn the quarter
- Citadel Advisors (Griffin)In the quarter-56%
- Millennium Mgmt (Englander)In the quarter-51%
- D.E. ShawIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Renaissance Technologies | 3.33M | -5.3% | $404M | 0.55% |
| AQR Capital | 5.58M | +4.9% | $677M | 0.20% |
| Bridgewater (Dalio) | 203.8K | +21% | $25M | 0.11% |
| Glenview Capital | 5,000 | $600.0K | 0.01% | |
| Citadel Advisors (Griffin) | 62.8K | -56% | $7.6M | 0.00% |
| Millennium Mgmt (Englander) | 40.2K | -51% | $4.9M | 0.00% |
| D.E. Shaw | – | – | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 5.04% of its shares outstanding were held short, +0.4% since the report before.
- Shares held short
- 10.03M
- 5.04%
- Since the report before9.99M on Sep 30, 2026
- +0.4%
- 5.3
- 1.89M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 64%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 9.10M
- Nov 15, 2023: Shares held short 9.26M
- Nov 30, 2023: Shares held short 8.27M
- Dec 15, 2023: Shares held short 6.97M
- Dec 29, 2023: Shares held short 6.31M
- Jan 12, 2024: Shares held short 5.23M
- Jan 31, 2024: Shares held short 6.98M
- Feb 15, 2024: Shares held short 8.70M
- Feb 29, 2024: Shares held short 7.77M
- Mar 15, 2024: Shares held short 7.91M
- Mar 28, 2024: Shares held short 8.06M
- Apr 15, 2024: Shares held short 8.27M
- Apr 30, 2024: Shares held short 9.64M
- May 15, 2024: Shares held short 7.54M
- May 31, 2024: Shares held short 11.66M
- Jun 14, 2024: Shares held short 18.72M
- Jun 28, 2024: Shares held short 16.93M
- Jul 15, 2024: Shares held short 12.81M
- Jul 31, 2024: Shares held short 12.15M
- Aug 15, 2024: Shares held short 11.76M
- Aug 30, 2024: Shares held short 10.80M
- Sep 13, 2024: Shares held short 9.64M
- Sep 30, 2024: Shares held short 6.80M
- Oct 15, 2024: Shares held short 7.35M
- Oct 31, 2024: Shares held short 7.42M
- Nov 15, 2024: Shares held short 7.00M
- Nov 29, 2024: Shares held short 5.99M
- Dec 13, 2024: Shares held short 5.87M
- Dec 31, 2024: Shares held short 5.10M
- Jan 15, 2025: Shares held short 5.04M
- Jan 31, 2025: Shares held short 5.79M
- Feb 14, 2025: Shares held short 8.32M
- Feb 28, 2025: Shares held short 5.85M
- Mar 14, 2025: Shares held short 6.36M
- Mar 31, 2025: Shares held short 7.19M
- Apr 15, 2025: Shares held short 7.42M
- Apr 30, 2025: Shares held short 6.41M
- May 15, 2025: Shares held short 9.47M
- May 30, 2025: Shares held short 8.43M
- Jun 13, 2025: Shares held short 8.19M
- Jun 30, 2025: Shares held short 7.29M
- Jul 15, 2025: Shares held short 7.12M
- Jul 31, 2025: Shares held short 7.42M
- Aug 15, 2025: Shares held short 9.60M
- Aug 29, 2025: Shares held short 7.51M
- Sep 15, 2025: Shares held short 8.70M
- Sep 30, 2025: Shares held short 8.50M
- Oct 15, 2025: Shares held short 9.36M
- Oct 31, 2025: Shares held short 9.52M
- Nov 14, 2025: Shares held short 9.50M
- Nov 28, 2025: Shares held short 9.15M
- Dec 15, 2025: Shares held short 10.75M
- Dec 31, 2025: Shares held short 10.54M
- Jan 15, 2026: Shares held short 10.80M
- Jan 30, 2026: Shares held short 11.19M
- Feb 13, 2026: Shares held short 11.01M
- Feb 27, 2026: Shares held short 11.01M
- Mar 13, 2026: Shares held short 11.04M
- Mar 31, 2026: Shares held short 11.44M
- Apr 15, 2026: Shares held short 11.97M
- Apr 30, 2026: Shares held short 11.36M
- May 15, 2026: Shares held short 11.04M
- May 29, 2026: Shares held short 11.40M
- Jun 15, 2026: Shares held short 10.56M
- Jun 30, 2026: Shares held short 10.58M
- Jul 15, 2026: Shares held short 10.51M
- Jul 31, 2026: Shares held short 10.25M
- Aug 14, 2026: Shares held short 9.39M
- Aug 31, 2026: Shares held short 9.36M
- Sep 15, 2026: Shares held short 9.98M
- Sep 30, 2026: Shares held short 9.99M
- Oct 15, 2026: Shares held short 10.03M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading57.8% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 57.8% of the shares in the reported trades were short sales, against 77.2% in the 14 before.
- Last 14 sessionsNov 2, 2026 – Nov 19, 2026
- 57.8%
- The 14 beforeOct 13, 2026 – Oct 30, 2026
- 77.2%
- Change
- -19.4 pts
- Short sales a dayon average, of 522.0K shares
- 301.9K
- More than atof 3,666 US-listed companies, same days
- 76%
- Median of alleight in ten from 34.5% to 63.8%
- 50.4%
- Short sales
- Oct 13, 2026: Short sales 77.6%
- Oct 14, 2026: Short sales 71.3%
- Oct 15, 2026: Short sales 67.6%
- Oct 16, 2026: Short sales 71.8%
- Oct 19, 2026: Short sales 59.4%
- Oct 20, 2026: Short sales 72.2%
- Oct 21, 2026: Short sales 77.8%
- Oct 22, 2026: Short sales 87.4%
- Oct 23, 2026: Short sales 82.9%
- Oct 26, 2026: Short sales 74.2%
- Oct 27, 2026: Short sales 78.2%
- Oct 28, 2026: Short sales 79.2%
- Oct 29, 2026: Short sales 84.6%
- Oct 30, 2026: Short sales 81.5%
- Nov 2, 2026: Short sales 57.6%
- Nov 3, 2026: Short sales 61.3%
- Nov 4, 2026: Short sales 48.7%
- Nov 5, 2026: Short sales 53.7%
- Nov 6, 2026: Short sales 53.8%
- Nov 9, 2026: Short sales 50.9%
- Nov 10, 2026: Short sales 47%
- Nov 11, 2026: Short sales 67%
- Nov 12, 2026: Short sales 64.9%
- Nov 13, 2026: Short sales 61%
- Nov 16, 2026: Short sales 60.2%
- Nov 17, 2026: Short sales 75.6%
- Nov 18, 2026: Short sales 57.2%
- Nov 19, 2026: Short sales 58.8%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Baker Bros. Advisors LpDirectorDirectly31.63M
- Herve HoppenotDirectorDirectly329.6K
- Pablo J CagnoniPresident, Global Head of R&DDirectly183.2K
- William MeuryChief Executive OfficerDirectly183.1K
- Mohamed Khairie IssaEVP, Head of U.S. CommercialDirectly63.9K
- Patrick A MayesEVP & Chief Scientific OfficerDirectly61.4K
- Vijay K IyengarEVP, GMAPPSDirectly40.5K
- Jonathan Elliott DickinsonEVP, General Manager, EuropeDirectly36.4K
- Barry P FlannellyEVP & General Manager USDirectly35.1K
- Steven H SteinCMO & Head of Late-Stage Dev.Directly30.9K
- Michael James MorrisseyEVP, Head of Tech. OperationsDirectly27.5K
- Lee HeesonEVP, Head of Incyte IntlDirectly26.9K
- Sheila A. DentonEVP & General CounselDirectly26.6K
- Paul J ClancyDirectorDirectly25.8K
- Jean Jacques BienaimeDirectorDirectly24.4K
- Edmund HarriganDirectorDirectly23.2K
- Thomas TrayPrincipal Accounting OfficerDirectly21.1K
- Jacqualyn A FouseDirectorDirectly21.0K
- Richard A. HoffmanEVP & General CounselDirectly16.9K
- David H GardnerEVP, Chief Strategy OfficerDirectly15.9K
- Katherine A HighDirectorDirectly15.0K
- Otis W BrawleyDirectorDirectly12.9K
- Ramitpal K BasiEVP, Human ResourcesDirectly11.0K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Baker Bros. Advisors LpDirector | 31.63M | – | Sep 30, 2026 | Form 4 |
| Herve HoppenotDirector | 329.6K | – | Nov 10, 2025 | Form 4 |
| Pablo J CagnoniPresident, Global Head of R&D | 183.2K | – | Nov 16, 2026 | Form 4 |
| William MeuryChief Executive Officer | 183.1K | – | Jul 16, 2026 | Form 4 |
| Mohamed Khairie IssaEVP, Head of U.S. Commercial | 63.9K | – | Jul 16, 2026 | Form 4 |
| Patrick A MayesEVP & Chief Scientific Officer | 61.4K | – | Aug 5, 2026 | Form 4 |
| Vijay K IyengarEVP, GMAPPS | 40.5K | – | Jul 16, 2025 | Form 4 |
| Jonathan Elliott DickinsonEVP, General Manager, Europe | 36.4K | – | Sep 12, 2024 | Form 4 |
| Barry P FlannellyEVP & General Manager US | 35.1K | – | Jul 16, 2025 | Form 4 |
| Steven H SteinCMO & Head of Late-Stage Dev. | 30.9K | – | Nov 16, 2026 | Form 4 |
| Michael James MorrisseyEVP, Head of Tech. Operations | 27.5K | – | Dec 17, 2025 | Form 4 |
| Lee HeesonEVP, Head of Incyte Intl | 26.9K | – | Nov 13, 2026 | Form 4 |
| Sheila A. DentonEVP & General Counsel | 26.6K | – | Nov 17, 2025 | Form 4 |
| Paul J ClancyDirector | 25.8K | – | Sep 30, 2026 | Form 4 |
| Jean Jacques BienaimeDirector | 24.4K | – | Jun 8, 2026 | Form 4 |
| Edmund HarriganDirector | 23.2K | – | Sep 30, 2026 | Form 4 |
| Thomas TrayPrincipal Accounting Officer | 21.1K | – | Nov 3, 2026 | Form 4 |
| Jacqualyn A FouseDirector | 21.0K | – | Jun 8, 2026 | Form 4 |
| Richard A. HoffmanEVP & General Counsel | 16.9K | – | Jul 16, 2026 | Form 4 |
| David H GardnerEVP, Chief Strategy Officer | 15.9K | – | Sep 22, 2026 | Form 4 |
| Katherine A HighDirector | 15.0K | – | Jun 8, 2026 | Form 4 |
| Otis W BrawleyDirector | 12.9K | – | Jun 8, 2026 | Form 4 |
| Ramitpal K BasiEVP, Human Resources | 11.0K | – | Aug 25, 2026 | Form 4 |
A lower bound: it counts only the 23 officers and directors with a market trade since Nov 21, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
10b5-1 trading plans
Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.
- Lee HeesonExecutive Vice President and Head of Incyte InternationalWhat happenedAdoptedAug 14, 2026Shares10.7K
- Thomas TrayVice President, Finance and Chief Accounting OfficerWhat happenedAdoptedJul 31, 2026Shares4,128
- Pablo CagnoniPresident and Global Head of Research and Development,What happenedAdoptedApr 30, 2026Shares139.4K
- Patrick MayesExecutive Vice President, Chief Scientific OfficerWhat happenedAdoptedApr 29, 2026Shares52.1K
- Steven SteinChief Medical Officer and Head of Late-Stage DevelopmentWhat happenedAdoptedMar 16, 2026Shares207.5K
- Thomas TrayVice President, Chief Accounting OfficerWhat happenedAdoptedFeb 24, 2026Shares4,690
- Paul ClancydirectorWhat happenedAdoptedFeb 12, 2026Shares15.0K
- Pablo CagnoniPresident, Research and DevelopmentWhat happenedAdoptedNov 20, 2025Shares56.0K
- Michael MorrisseyExecutive Vice President, Head of Global Technical OperationsWhat happenedAdoptedSep 16, 2025Shares58.3K
- Mohamed IssaExecutive Vice President, Head of US OncologyWhat happenedAdoptedSep 15, 2025Shares11.8K
| Person | What happened | Until | Shares | Filing |
|---|---|---|---|---|
| Lee HeesonExecutive Vice President and Head of Incyte International | AdoptedAug 14, 2026 | Aug 17, 2027 | 10.7K | 10-Q |
| Thomas TrayVice President, Finance and Chief Accounting Officer | AdoptedJul 31, 2026 | Jul 31, 2027 | 4,128 | 10-Q |
| Pablo CagnoniPresident and Global Head of Research and Development, | AdoptedApr 30, 2026 | May 1, 2028 | 139.4K | 10-Q |
| Patrick MayesExecutive Vice President, Chief Scientific Officer | AdoptedApr 29, 2026 | Apr 29, 2027 | 52.1K | 10-Q |
| Steven SteinChief Medical Officer and Head of Late-Stage Development | AdoptedMar 16, 2026 | Mar 17, 2027 | 207.5K | 10-Q |
| Thomas TrayVice President, Chief Accounting Officer | AdoptedFeb 24, 2026 | Feb 24, 2027 | 4,690 | 10-Q |
| Paul Clancydirector | AdoptedFeb 12, 2026 | Feb 12, 2027 | 15.0K | 10-Q |
| Pablo CagnoniPresident, Research and Development | AdoptedNov 20, 2025 | Nov 20, 2026 | 56.0K | 10-K |
| Michael MorrisseyExecutive Vice President, Head of Global Technical Operations | AdoptedSep 16, 2025 | Sep 16, 2026 | 58.3K | 10-Q |
| Mohamed IssaExecutive Vice President, Head of US Oncology | AdoptedSep 15, 2025 | Sep 15, 2026 | 11.8K | 10-Q |
As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.
Executive pay
From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.
$6.4M
Actually paid: $23M
$32M
Actually paid: $55M
$6.3M
Actually paid: $9.7M
–
total product revenues
$4.4B
From the proxy statement (DEF 14A) of Apr 28, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A
Share repurchases
How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.
- Jun 30, 202410-QAmount$2.0B
| Quarter | Shares | Average price | Amount | Left in the program | Filing |
|---|---|---|---|---|---|
| Jun 30, 202410-Q | 33.33M | $60.00 | $2.0B | – | 10-Q |
From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price.
The shareholders' vote on pay
The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.
- 2026Jun 9, 2026For83.9%
- 2025Jun 11, 2025For92.2%
- 2024Jun 14, 2024For89.6%
- 2023Jun 15, 2023For87.7%
- 2022Jun 16, 2022For90.6%
- 2021May 27, 2021For92.6%
| Year | For | Votes for | Votes against | Abstentions | Broker non-votes | Filing |
|---|---|---|---|---|---|---|
| 2026Jun 9, 2026 | 83.9% | 146M | 28.08M | 290.9K | 11.43M | 8-K |
| 2025Jun 11, 2025 | 92.2% | 154M | 13.02M | 571.3K | 9.52M | 8-K |
| 2024Jun 14, 2024 | 89.6% | 172M | 19.94M | 336.2K | 11.06M | 8-K |
| 2023Jun 15, 2023 | 87.7% | 169M | 23.66M | 241.9K | 12.32M | 8-K |
| 2022Jun 16, 2022 | 90.6% | 171M | 17.79M | 82.0K | 11.71M | 8-K |
| 2021May 27, 2021 | 92.6% | 176M | 14.04M | 89.4K | 10.88M | 8-K |
From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- RPGInvesco S&P 500 Pure Growth ETFWeight in the fund1.81%
- IBBiShares Biotechnology ETFWeight in the fund1.75%
- VFLOVictoryShares Free Cash Flow ETFWeight in the fund1.74%
- CALFPacer US Small Cap Cash Cows 100 ETFWeight in the fund1.52%
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund1.00%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.77%
- FMDEFidelity Enhanced Mid Cap Core ETFWeight in the fund0.64%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.54%
- COWZPacer US Cash Cows 100 ETFWeight in the fund0.50%
- USMViShares MSCI USA Min Vol Factor ETFWeight in the fund0.46%
58 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 715
- Q4 2025: Managers 824
- Q1 2026: Managers 819
- Q2 2026: Managers 859
Institutional investors by quarter
The fund managers holding INCY, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 859 managers held 203M shares, worth $23.0B. During the quarter 124 opened a position, 84 closed one, 354 added and 268 trimmed.
The largest holders, Q2 2026
- Baker Bros. AdvisorsIn the quarter
- BlackRockIn the quarter-5.0%
- Dodge & CoxIn the quarter-2.4%
- Vanguard Capital ManagementIn the quarter+0.9%
- State StreetIn the quarter+0.8%
- Vanguard Portfolio ManagementIn the quarter+0.4%
- AQR CapitalIn the quarter-8.4%
- Geode Capital ManagementIn the quarter+1.0%
- LSV Asset ManagementIn the quarter+5.2%
- InvescoIn the quarter+5.4%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Baker Bros. Advisors | 30.76M | $3.5B | |
| BlackRock | 18.03M | -5.0% | $2.0B |
| Dodge & Cox | 11.96M | -2.4% | $1.4B |
| Vanguard Capital Management | 11.02M | +0.9% | $1.2B |
| State Street | 9.72M | +0.8% | $1.1B |
| Vanguard Portfolio Management | 7.79M | +0.4% | $883M |
| AQR Capital | 5.32M | -8.4% | $603M |
| Geode Capital Management | 4.75M | +1.0% | $537M |
| LSV Asset Management | 4.12M | +5.2% | $467M |
| Invesco | 4.08M | +5.4% | $463M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
The full analysis
What do Incyte's filings show?
Who buys and sells is one part of Incyte's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have INCY's insiders bought or sold?
From May 28, 2026 to Nov 18, 2026 Incyte's insiders bought 0 and sold $49M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold INCY?
7 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $677M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.